HCV quasispecies evolution during treatment with interferon alfa-2b and ribavirin in two children coinfected with HCV and HIV-1

被引:15
|
作者
Quesnel-Vallieres, Mathieu [1 ,4 ]
Lemay, Mireille [2 ,5 ]
Lapointe, Normand [2 ,5 ]
Martin, Steven R. [3 ,5 ]
Soudeyns, Hugo [1 ,4 ,5 ]
机构
[1] CHU St Justine, Ctr Rech, Unite Immunopathol Virale, Montreal, PQ H3T 1C5, Canada
[2] CHU St Justine, Ctr Rech, Ctr Maternal & Infantile SIDA, Montreal, PQ H3T 1C5, Canada
[3] CHU St Justine, Ctr Rech, Serv Gastroenterol & Nutr, Montreal, PQ H3T 1C5, Canada
[4] Univ Montreal, Dept Microbiol & Immunol, Montreal, PQ H3C 3J7, Canada
[5] Univ Montreal, Fac Med, Dept Pediat, Montreal, PQ H3C 3J7, Canada
关键词
Hepatitis C virus; Coinfection; Pediatrics; Mother-to-child transmission; Interferon; Ribavirin;
D O I
10.1016/j.jcv.2008.06.019
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Two children who acquired hepatitis C virus (HCV) and human immunodeficiency virus type 1 (HIV-1) infection by mother-to-child transmission were monitored during interferon alfa-2b and ribavirin treatment. In Patient C1, CD4(+) T cell counts were within normal range and HIV-1 viral load was undetectable. HCV viral load declined slightly following treatment initiation while novel variants rapidly emerged, indicative of quasispecies diversification. In Patient C2, CD4(+) T cell counts were low and HIV-1 replication was not fully controlled by antiretroviral therapy. HCV viral load rose during treatment and a striking conservation of the variant spectrum was observed. In both cases, there was no decline in quasispecies complexity following treatment initiation and sustained virological response was not achieved. These results suggest that reduction in quasispecies complexity, which is observed in adult responders following interferon treatment, may be mechanistically unrelated with evolution of the variant profile and/or selective pressure exerted on HCV. (C) 2008 Elsevier B.V. All rights reserved
引用
收藏
页码:236 / 240
页数:5
相关论文
共 50 条
  • [21] A randomized trial of daclatasvir with peginterferon alfa-2b and ribavirin for HCV genotype 1 infection
    Suzuki, Fumitaka
    Toyota, Joji
    Ikeda, Kenji
    Chayama, Kazuaki
    Mochida, Satoshi
    Hayashi, Norio
    Ishikawa, Hiroki
    Miyagoshi, Hidetaka
    Hu, Wenhua
    McPhee, Fiona
    Hughes, Eric A.
    Kumada, Hiromitsu
    ANTIVIRAL THERAPY, 2014, 19 (05) : 491 - 499
  • [22] HCV quasispecies dynamics during combination therapy of peginterferon alfa 2A and ribavirin
    Fan, XF
    Droll, DA
    Xu, YJ
    Chambers, TJ
    Di Bisceglie, AM
    GASTROENTEROLOGY, 2003, 124 (04) : A776 - A777
  • [23] Evolution of T-cell responses to hepatitis C virus (HCV) during pegylated interferon plus ribavirin treatment in HCV-monoinfected and in HCV/HIV-coinfected patients
    Capa, Laura
    Soriano, Vincent
    Garcia-Samaniego, Javier
    Nunez, Marina
    Romero, Miriam
    de Mendoza, Carmen
    Cascajero, Almudena
    Munoz, Fernando
    Gonzalez-Lahoz, Juan
    Benito, Jose M.
    ANTIVIRAL THERAPY, 2007, 12 (04) : 459 - 468
  • [24] Real life experience in treatment of HIV-1/HCV-coinfected patients with pegylated interferon alpha and ribavirin: predictors of SVR
    Bruno, Giuseppe
    Fasano, Massimo
    Saracino, Annalisa
    Volpe, Anna
    Bartolomeo, Nicola
    Ladisa, Nicoletta
    Maggi, Paolo
    Monno, Laura
    Angarano, Gioacchino
    NEW MICROBIOLOGICA, 2015, 38 (01): : 21 - 27
  • [25] Impact of taribavirin and ribavirin exposure on efficacy and anemia rates when combined with pegylated interferon alfa-2b in the treatment of chronic HCV
    Jacobson, Ira
    Pockros, Paul
    Benhamou, Yves
    Esteban-Mur, Rafael
    Lurie, Yoav
    Flisiak, Robert
    Afdhal, Nezam
    Kim, Yong
    Xu, Yi
    Murphy, Brian
    HEPATOLOGY, 2006, 44 (04) : 610A - 610A
  • [26] CHILDREN WITH HCV INFECTION SHOW HIGH SUSTAINED VIROLOGIC RESPONSE RATES ON PEGINTERFERON ALFA-2B PLUS RIBAVIRIN TREATMENT
    Wirth, Stefan
    Ribes-Koninckx, Carmen
    Bortolotti, Flavia
    Zancan, Lucia
    Jara, Paloma
    Shelton, Mark M.
    Kerkar, Nanda
    Galoppo, Cristina
    Rodriguez-Baez, Norberto
    Ciocca, Mirta
    Lachaux, Alain
    Lacaille, Florence
    Lang, Thomas
    Kullmer, Ulrike
    Huber, Wolf Dietrich
    Gonzalez, Teresita
    Pollack, Henry
    Alonso, Estella M.
    Broue, Pierre
    Ramakrishna, Jyoti
    Neigut, Deborah
    Del Valle-Segarra, Antonio I.
    Hunter, Bessie A.
    Brass, Clifford A.
    Noviello, Stephanie
    Sniukiene, Vilma
    Harvey, Joann
    Albrecht, Janice K.
    HEPATOLOGY, 2008, 48 (04) : 392A - 393A
  • [27] 24 weeks of treatment with peg-interferon alfa-2b plus ribavirin in patients infected with HCV genotype 2 and 3.
    Wiegand, J
    HEPATOLOGY, 2002, 36 (04) : 360A - 360A
  • [28] Autoimmune hemolytic anemia in HCV/HIV coinfected patients during treatment with pegylated alpha-2a interferon plus ribavirin
    Vilar, Fernando Crivelenti
    de Castro, Gleusa
    Moya, Maria Janete
    Candolo Martinelli, Ana de Lourdes
    De Santis, Gil Cunha
    Nunes da Cunha Cozac, Ana Paula Costa
    de Castro Figueiredo, Jose Fernando
    REVISTA DA SOCIEDADE BRASILEIRA DE MEDICINA TROPICAL, 2007, 40 (06) : 678 - 680
  • [29] Efficacy of interferon alpha-2b plus ribavirin combination therapy in HIV/HCV coinfected patients
    Oliver, DL
    Stewart, M
    Chatfield, E
    Aronson, N
    Selim, K
    Mathew, C
    Hassanein, T
    GASTROENTEROLOGY, 2002, 123 (01) : 77 - 77
  • [30] Early HCV-RNA decline during treatment with PEG-interferon alfa-2b plus ribavirin or conventional interferon alfa 2b plus ribavirin: Analysis of 80 patients treated at a single center.
    Cornberg, M
    Hadem, J
    Bastuerk, M
    Tillmann, HL
    Schueler, A
    Kothe, N
    Jaeckel, E
    Trautwein, C
    Wedemeyer, H
    Manns, MP
    HEPATOLOGY, 2001, 34 (04) : 217A - 217A